Lattice Medical and the EIC Accelerator: Regrowing the Breast

Women who lose a breast to cancer surgery can have it reconstructed, and Lattice Medical wants that done with their own tissue rather than a permanent implant. Lattice Medical, a company in Loos near Lille, 3D-prints MATTISSE, a resorbable chamber placed under the skin that guides the patient's own fat tissue to regrow the breast over about six months, after which the device dissolves.

The European Innovation Council granted €2,438,488 towards a €3.48 million project that started clinical trials and scaled up production. In October 2025 Lattice raised €43 million, with the EIC Fund among its existing shareholders. The first-in-human study finished enrolling its first 10 patients in March 2025, and published results cover one patient.

Where Lattice Medical Stands Today

The €43 million Series B was led by the SPI fund, managed by Bpifrance for France 2030, with Blast.Club, Sprim and a group of private investors, alongside existing shareholders including the EIC Fund. Lattice said it would use the money for clinical development of MATTISSE and RODIN towards launch in France and abroad, to build its own manufacturing capacity and to grow Lattice Services, a contract manufacturing arm. It said MATTISSE is in clinical trials at seven centres in France and Spain. The latest accounts in the French register data, for 2024, show revenue of zero and a net loss of €1.52 million.

The Technology: A Scaffold That Disappears

MATTISSE is a 3D-printed, resorbable "bioprothesis" implanted in a surgery of about an hour and a half. It gives shape to the new tissue and is absorbed as the patient's fat fills it. In September 2024 Lattice received €3.6 million from France 2030 for M3DINPRINT, which it describes as "the first 3D printing farm in a cleanroom capable of manufacturing on large volumes".

What the EIC Project Promised, and What CORDIS Shows

The project promised breast reconstruction with patients' own tissue. The CORDIS report describes one patient, aged 63, followed for 18 months with "remarkable total breast reconstruction within six months" and no adverse effects, trial approvals in Georgia in 2022 and France in 2023, and 16 3D printers installed in an ISO 7 clean room towards a capacity of up to 1,500 implants a year. The French TIDE trial opened in Lille, Paris and Strasbourg. On ClinicalTrials.gov, the study started in July 2022, plans 50 patients, is listed as recruiting and expects primary completion in July 2027. Lattice's news page reports ISO 13485 certification in September 2026 and €2.15 million for a project called MEDCO2 in July 2026, but no CE mark or results from the first 10 patients. On 17 March 2025 Lattice announced that the first, safety phase of the TIDE study had enrolled 10 patients in France and Spain, followed by six months of observation.

1. First-in-human useDeliveredFirst patient reconstructed.
2. Trial approvalsDeliveredGeorgia 2022, France 2023.
3. Scaled manufacturingPartial16 printers; 1,500 a year planned.
4. Clinical evidence at scaleNot shownOne patient reported.

What Has Happened Since the Award

The Money

The award was blended finance, and the EIC Fund is named as a historical shareholder in the 2025 announcement; the amount it invested is not public. The Series B also drew on non-dilutive France 2030 programmes and bank financing.

Why Europe Should Care

Regrowing tissue after cancer surgery, rather than inserting a permanent implant, would be a new option for women after mastectomy. Lattice is building both the device and a French manufacturing base for it, with French and EU public money behind both.

The Verdict

Lattice Medical has not been asked for comment for this article. It is based entirely on company statements, EU project data, the trial registry and the French company register, linked throughout.